Femasys Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Femasys Inc 's ROA in the second quarter of 2026?
Femasys Inc recorded a cumulative net loss of $-12 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -35.39%.

However, within the Healthcare sector 678 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4147, from total ROA ranking in the first quarter of 2026 at 5008.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	3.33 %	24.23 %	759.68 %	4.52 %	-32.04 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-12	-12	-19	-20	-21
Return On Assets (TTM)	-35.39 %	-35.84 %	-55.11 %	-146.59 %	-157.63 %
FEMY's Total Ranking	# 4147	# 5008	# 4499	# 4597	# 4646
Total Assets (TTM) in million	14	16	92	16	14
Seq. Total Assets Change	-13.68 %	-82.04 %	463.85 %	18.21 %	3.79 %
Seq. Net Income Change	-	-	-	-	-

FEMY's 5 Years Annual ROA >> Back to FEMY Management Effectiveness >> Compare FEMY ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 161
Sector	# 679
Overall	# 4117

Return On Assets Statistics
High	Average	Low
-9.67 %	-82.03 %	-152.59 %
(Mar 31 2022)		(Jun 30 2025)

News about Femasys Inc Return on Assets ROA

Femasys Launches FemaSeed: Pioneering Infertility Care with Strategic Partnerships Amidst Financial Challenges

In a significant development within the realm of women s reproductive healthcare, Femasys Inc. has announced the establishment of vital distribution partnerships aimed at bringing its innovative FemaSeed infertility treatment into the spotlight. This initiative sees leading medical clinics from coast to coast in the United States and ventures into the European and Spanish markets, positioning FemaSeed as a crucial resource for fertility care. These partnerships come at a pivotal time for Femasys, which recently reported a staggering cumulative net loss of $17 million for the twelve months ending in the second quarter of 2024. Compounding the situation is a troubling return on investment (ROI) figure of -93.73% that has raised concerns about the company s financial sustainability. The share price remained stagnant at 0% during the third quarter of 2024, underlining the urgent need for strategic maneuvers to propel the company s fortunes forward.With the strategic distribution agreements formed with Comercial Medico Quirurgica, SA, and Durgalab, Femasys is determined to enhance its penetration in both the Spanish and broader European markets. These distributors will be crucial in facilitating the introduction of the CE-marked FemaSeed device—designed to support women’s reproductive health—into these new territories. The expected partnership will catalyze product awareness and acceptance, potentially generating new revenue streams that could help alleviate the pressing financial concerns faced by the company.

Financial Statements
Femasys Inc 's Assets	$ 14 million	FEMY's Balance sheet
Femasys Inc 's Income	$ -4 million	Quarterly FEMY's Income Statement
FEMY's Income by Division		See FEMY's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	759.68 %	-61.51 %	64.28 %	-40.2 %	-
Total Assets in million	92	11	28	17	28
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-19	-19	-14	-11	-8
Annual Return On Assets	-20.28 %	-176.11 %	-51.33 %	-67.44 %	-26.68 %

FEMY's 5 Years Annual ROA >> Back to FEMY Management Effectiveness >> Compare FEMY ROA to its Competitors

More Return On Assets Ratios
FEMY's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
FEMY's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for FEMY's Competitors
Subscribers only: Roa for Femasys Inc 's Suppliers
Subscribers only: Return On Assets for FEMY's Customers

You may also want to know
FEMY's Roi	FEMY's Inventory Turnover Ratio	FEMY's Growth Rates	FEMY's Dividend Comparisons
	FEMY's Profitability Ratios	FEMY's Asset Turnover Ratio	FEMY's Dividend Growth
FEMY's Roe	FEMY's Valuation Ratios	FEMY's Financial Strength Ratios	FEMY's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:40:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.